跳至主要内容
临床试验/NCT00654082
NCT00654082已完成4 期

A Placebo-Controlled, Randomized, Two-Way Cross-Over, Double-Blind, Flexible Dose, Multicenter Study to Evaluate the Efficacy and Safety of Viagra in Male Patients With Traumatic Spinal Cord Injury and Erectile Dysfunction

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1 个研究点 分布在 1 个国家目标入组 88 人开始时间: 2002年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
88
试验地点
1
主要终点
The proportion of subjects who indicated a preference for either treatment and who said that the treatment improved their erections

研究概览

简要总结

To demonstrate the efficacy, safety and tolerability of sildenafil administered orally, as required, approximately 1 hour prior to sexual activity to men with erectile dysfunction (ED) associated with spinal cord injury (SCI), as well as its effects on the quality of life (QoL) of these patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Patients were men with spinal cord injury and erectile dysfunction

排除标准

  • 未提供

研究组 & 干预措施

Arm 1

Active Comparator

干预措施: sildenafil (Drug)

Arm 2

Placebo Comparator

干预措施: placebo (Drug)

结局指标

主要结局

The proportion of subjects who indicated a preference for either treatment and who said that the treatment improved their erections

时间窗: Weeks 6 and 14

次要结局

  • Responses to the Global Efficacy Assessment (GEA) Question(Weeks 0, 6, 8, and 14)
  • Responses to questions on the Quality of Life (QoL) Questionnaire(Weeks 0, 6, 8, and 14)
  • Responses to the International Index of Erectile Function (IIEF)(Weeks 0, 6, 8, and 14)
  • Intercourse success rate derived from patient event log(Weeks 0, 6, 8, and 14)
  • Responses to Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questions(Weeks 0, 6, 8, and 14)

研究者

发起方
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

A Study Evaluating the Efficacy and Safety of... | 临床试验